Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Esanex Inc.44 enrolled

Overview

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cancer

Interventions

SNX-5422DRUG

dose escalated, tablets every other day; undetermined duration until disease progression

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>18 years old * histologically confirmed solid tumor malignancy * refractory to available therapy or for which no therapy is available * adequate organ function Exclusion Criteria: * CNS malignancy * significant GI disease * at risk for prolonged QT interval

Locations (2)

Pfizer Investigational Site

Scottsdale, Arizona, United States

Pfizer Investigational Site

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

adverse events and other safety assessments

Time frame: continuous

Secondary Outcomes

tumor response measured by X-rays or scans

Time frame: after every 2 cycles

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.